Integrin receptor antagonists
    1.
    发明授权
    Integrin receptor antagonists 失效
    整合素受体拮抗剂

    公开(公告)号:US5760028A

    公开(公告)日:1998-06-02

    申请号:US770538

    申请日:1996-12-20

    CPC分类号: C07D401/12 C07D403/12

    摘要: This invention relates to novel heterocycles including 3-�1-�3-(imidazolin-2-ylamino)propyl!indazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)propionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

    摘要翻译: 本发明涉及包含3- [1- [3-(咪唑啉-2-基氨基)丙基]吲唑-5-基羰基氨基] -2-(苄氧基羰基氨基)丙酸的新型杂环,其可用作αvβ3的拮抗剂 整合素和相关细胞表面粘附蛋白受体,含有这些化合物的药物组合物,制备这些化合物的方法,以及使用这些化合物单独或与其它治疗剂组合用于抑制细胞粘附,血管生成 疾病,炎症,骨退化,癌转移,糖尿病性视网膜病变,血栓形成,再狭窄,黄斑变性以及由细胞粘附和/或细胞迁移和/或血管发生介导的其它病症。

    Integrin receptor antagonists
    2.
    发明授权
    Integrin receptor antagonists 失效
    整合素受体拮抗剂

    公开(公告)号:US5710159A

    公开(公告)日:1998-01-20

    申请号:US647132

    申请日:1996-05-09

    摘要: This invention relates to novel heterocycle compounds including but not limited to 3-�3-�3-(imidazolin-2-yl amino)propyloxy!isoxazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)-propionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 and related integrin receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion and the treatment of angiogenic disorders, inflammation, bone degradation, tumors, metastases, thrombosis, and other cell aggregation-related conditions.

    摘要翻译: 本发明涉及包括但不限于3- [3- [3-(咪唑啉-2-基氨基)丙氧基]异恶唑-5-基羰基氨基] -2-(苄氧基羰基氨基) - 丙酸的新型杂环化合物,其可用作 αvβ3和相关整联蛋白受体的拮抗剂,含有这些化合物的药物组合物,制备此类化合物的方法,以及使用这些化合物单独或与其它治疗剂组合用于抑制细胞粘附和 血管生成障碍,炎症,骨退化,肿瘤,转移,血栓形成和其他细胞聚集相关病症的治疗。

    Isoxazoline fibrinogen receptor antagonists
    10.
    发明授权
    Isoxazoline fibrinogen receptor antagonists 有权
    异恶唑啉纤维蛋白原受体拮抗剂

    公开(公告)号:US06476226B2

    公开(公告)日:2002-11-05

    申请号:US09905321

    申请日:2001-07-13

    IPC分类号: C07D21500

    摘要: This invention relates to novel isoxazolines and isoxazoles of formula (I): or a pharmaceutically acceptable salt or prodrug form thereof. The invention relates to novel isoxazolines which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

    摘要翻译: 本发明涉及新的式(I)的异恶唑和异恶唑:或其药学上可接受的盐或前药形式。 本发明涉及可用作血小板糖蛋白IIb / IIIa纤维蛋白原受体复合物的拮抗剂的新型异恶唑类,含有这些化合物的药物组合物,制备这些化合物的方法,以及使用这些化合物单独或与其它治疗剂 用于抑制血小板聚集,作为血栓溶解剂,和/或用于治疗血栓栓塞性疾病。